Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - July 2011


Expertise in Neuropharmacology





Summer News

Neurolixis Inc.: biopharma start-up

In the present climate of pharmaceutical industry restructuring, Adrian Newman-Tancredi Ph.D., with other experienced neuroscience researchers, has co-founded
a CNS-focused drug discovery and early development start-up. Neurolixis Inc. is actively pursuing discussions aimed at establishing research partnerships.

For more information or if you are interested in risk-sharing collaborations, click here.


ECNP Brainstorming Session

Adrian Newman-Tancredi Ph.D. will be presenting at the 24th meeting of the ECNP (European College of Neuropsychopharmacology)
on Tuesday 6 September 2011 in Paris, France (session BS.7).
Session title:

"Antipsychotics in the post-patent cliff era: challenges for clinical and drug discovery research".

If you are attending the ECNP meeting, why not call Adrian and learn more about his work on antipsychotics.
For information click here.















NeuroAct Communication is an independent consulting service founded by Adrian Newman-Tancredi Ph.D.,
an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile

Note: Adrian is progressively transitioning to take up full-time research  management responsabilities at Neurolixis Inc.



NeuroAct Communication has advised diverse lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.



Scientific Communication

Just Published

Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders.
Newman-Tancredi A.
Neuropsychiatry, Vol. 1, No. 2, Pages 149-164.

Recent studies have shown that agonists acting at G-protein coupled receptors (GPCRs) can preferentially activate certain signalling responses. This phenomenon is known as "biased agonism" or "functional selectivity". The present review examines the evidence for "biased agonism" at serotonin 5-HT1A receptors, notably as regards the preferential post-synaptic agonist, F15599. Preferential activation of post-synaptic cortical 5-HT1A receptors is a promising strategy for management of a variety of disorders including depression and cognitive deficits.

To find out more about Adrian's scientific communication, see his Publications.